ExamWorks Group (NYSE: EXAM ) is expected to report Q1 earnings on May 8. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ExamWorks Group's revenues will grow 17.6% and EPS will remain in the red.
The average estimate for revenue is $145.6 million. On the bottom line, the average EPS estimate is -$0.07.
Last quarter, ExamWorks Group recorded revenue of $139.6 million. GAAP reported sales were 21% higher than the prior-year quarter's $115.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.08. GAAP EPS were -$0.08 for Q4 versus -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 33.7%, 40 basis points worse than the prior-year quarter. Operating margin was 1.4%, 300 basis points better than the prior-year quarter. Net margin was -1.9%, 250 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $605.7 million. The average EPS estimate is -$0.29.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 17 members out of 28 rating the stock outperform, and 11 members rating it underperform. Among nine CAPS All-Star picks (recommendations by the highest-ranked CAPS members), four give ExamWorks Group a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ExamWorks Group is outperform, with an average price target of $16.17.
Is ExamWorks Group the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add ExamWorks Group to My Watchlist.